TG Therapeutics Stock News

TG Therapeutics' (TGTX) CEO Mike Weiss on Q1 2021 Results - Earnings Call Transcript

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -32.69% and -20.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ULTRA-V Phase 2 trial has reached completion of patient enrollment ULTRA-V Phase 2 trial has reached completion of patient enrollment

TG Therapeutics: Hidden Value In Multiple Sclerosis

Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions

Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET Webcast to be held tomorrow, April 16, 2021 at 8:30 AM ET

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the UNITY-NHL Phase 2b trial evaluating UKONIQ™ (umbralisib), the Co

TG Therapeutics: Great Set Of Catalysts, Approvals This Year And Next

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that results of the ULTIMATE I & II Phase 3 trials evaluating ublituximab, the Company's novel, glyc

TG Therapeutics' (TGTX) CEO Michael Weiss on Q4 2020 Results - Earnings Call Transcript

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -24.56% and -5.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET